EU Proposes Measures to Boost Health Sector Innovation and Resilience

Key highlights
  • The Biotech Act aims to mobilize €10 billion investment for Europe's biotech sector.
  • Cardiovascular diseases cost the EU economy €282 billion annually.
  • Medical device reforms could save €3.3 billion per year, including €2.4 billion in administrative savings.
  • The Safe Hearts Plan sets clear goals for cardiovascular health improvements by 2035.

Overview

The European Commission has proposed measures to enhance the EU health sector's innovation, competitiveness, and resilience. This includes the Biotech Act, Safe Hearts Plan, and medical device reforms.

Biotech Act

The Biotech Act aims to boost Europe's biotechnology sector, which contributes €40 billion to the economy and employs over 900,000 people. It addresses funding gaps and regulatory barriers, promoting research and production within Europe. The Act will explore new funding methods and accelerate clinical trials, aiming to establish a leading health biotech industry.

Safe Hearts Plan

Cardiovascular diseases, the leading cause of premature death in the EU, cost the economy €282 billion annually. The Safe Hearts Plan is the first comprehensive EU approach to tackle this issue, focusing on prevention, detection, and treatment. It aims to reduce health inequalities and improve access to care, with goals set for 2035.

Medical Devices

The EU's medical device sector, valued at €170 billion, faces regulatory challenges. Proposed reforms aim to simplify rules, support digitalization, and ensure patient safety. The European Medicines Agency will play a stronger role in coordination and monitoring shortages. These changes could lead to €3.3 billion in annual savings, including €2.4 billion in administrative costs.

Next Steps

The legislative proposals will be submitted to the European Parliament and the Council for adoption. Implementation of the Safe Hearts Plan will begin in collaboration with Member States.

Source: EIB

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time.

Related articles

9 October 2026
CVMP meeting highlights — 6–8 Oct 2026

Positive opinions for Bovilis Lumpyvax and Stemyca; Mirataz SPC updated for overdose effects; Vaxxitek MA extended one year; Vetmedin re‑examination concluded positive by majority.

9 October 2026
EMA recommends Intervet's Bovilis Lumpyvax for lumpy skin disease

Live attenuated vaccine cuts clinical signs and viraemia from three weeks post‑vaccination and confers protection for one year; authorised under exceptional circumstances; side effects are uncommon.

1 October 2026
EMA opens first women's health multistakeholder workshop

Workshop to close gaps in research, diagnosis and treatment for women; aims to deliver a practical roadmap and public report to speed innovation and improve outcomes.

1 October 2026
EMA Management Board highlights — September 2026

Mid‑year operational results, NPL implementation progress, CTIS upgrade tied to the Biotech Act, and arrangements for the next Executive Director.

18 September 2026
Novo Nordisk’s Sogroya recommended by EMA CHMP for idiopathic short stature in children

Once-weekly somapacitan (Sogroya) receives CHMP positive opinion for children with idiopathic short stature; European Commission decision expected later this year.